Associated Papers
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
Tan L et al.
Nature Communications, 2024
Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection.
Thirunavukarasu D et al.
Genome Biology, 2021
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Joshi A et al.
Oncotarget, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.
Felsenstein KM et al.
Nature Reviews. Urology, 2018
Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z et al.
Plos One, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lee MS et al.
Cancer Research and Treatment, 2017
The evolving genomic landscape of urothelial carcinoma.
Glaser AP et al.
Nature Reviews. Urology, 2017
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M et al.
Clinical and Experimental Medicine, 2016
Integrated digital error suppression for improved detection of circulating tumor DNA.
Newman AM et al.
Nature Biotechnology, 2016
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Hedberg ML et al.
The Journal of Clinical Investigation, 2016
Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai H et al.
Acs Chemical Biology, 2015
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
Xu C et al.
Molecular Cancer Therapeutics, 2015
Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays.
Kenmotsu H et al.
Bmc Cancer, 2014
Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M et al.
Medical Oncology (northwood, London, England), 2014
Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Beyond histology: translating tumor genotypes into clinically effective targeted therapies.
Meador CB et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
Beauchamp EM et al.
Molecular Cancer Therapeutics, 2014
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
Pitini V et al.
Lung Cancer (amsterdam, Netherlands), 2013
Targeting genomic alterations in squamous cell lung cancer.
Mantripragada K et al.
Frontiers in Oncology, 2013
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS et al.
Cancer Discovery, 2011